A Phase 1 Study of SEA-TGT (SGN-TGT) in Subjects With Advanced Malignancies
What is the purpose of this trial?
This trial will look at a drug called SEA-TGT (also known as SGN-TGT) to find out whether it is safe for patients with solid tumors and lymphomas. It will study SEA-TGT to find out what its side effects are. A side effect is anything the drug does besides treating cancer. It will also study whether SEA-TGT works to treat solid tumors and lymphomas.
The study will have three parts. Part A of the study will find out how much SEA-TGT should be given to patients. Part B will use the dose found in Part A to find out how safe SEA-TGT is and if it works to treat solid tumors and lymphomas. Part C will study how well SEA-TGT with sasanlimab works to treat solid tumors.
- Trial withSeattle Genetics, Inc.
- Start Date10/28/2021
- End Date12/31/2022
- Last Updated11/15/2022
- Study HIC#2000027638